Riskpilot← Back to searchSign inGet full accessMundipharma Oy
OYActiveY-tunnus 1048595-3Rajatorpantie 41-BWholesale of pharmaceutical and medical goods · NACE 4646Est. 19961 employees
Revenue 2024
EUR 8,1M
+1% vs 2023
EBITDA margin
2.8%
-12% vs 2023
Equity ratio
83.7%
Financial strength
Net profit 2024
EUR 218K
-23% vs 2023
| Revenue | EUR 8,1M | +1% |
| EBITDA | EUR 228K | -12% |
| Net profit | EUR 218K | -23% |
| Total assets | EUR 8,5M | -33% |
| Equity | EUR 7,1M | +3% |
| Employees | 1 | — |
Legal name
Mundipharma Oy
Y-tunnus number
1048595-3
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. maaliskuuta 1996
Share capital
EUR 49 044
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on farmaseuttisten, kemikaalituotteiden, kosmeettisten tuotteiden tai yhdisteiden ja toalettitarvikkeiden kehittäminen, valmistuttaminen, rekisteröinti, maahantuonti, tukkukauppa ja markkinointi. Yhtiön toimialaan kuuluvat myös kliiniset tutkimukset. Yhtiö voi myös ryhtyä mihin tahansa yhtiön toimialaan suorasti tai epäsuorasti liittyvään kaupalliseen toimintaan tai muuhun yhtiön toimialaa tai tähän liittyvään edistävään toimintaan. Yhtiö voi hankkia ja käyttää suojattuja teollisuusoikeuksia, taitotietoa sekä lisenssejä yllämainittua tarkoitusta varten. Yhtiö voi myös omistaa ja hallita osakkeita, henkilöyhtiön osuuksia sekä kiinteistöjä.
Address
Rajatorpantie 41-B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 266 | 9 683 | 8 711 | 8 042 | 8 147 |
| Staff expenses | −1 305 | −500 | −142 | −154 | −149 |
| EBITDA | 1 119 | 398 | 257 | 258 | 228 |
| Depreciation & amort. | −6 | — | — | −0 | −0 |
| EBIT | 1 113 | 398 | 257 | 258 | 228 |
| Net financials | −1 | −6 | 4 | 91 | 53 |
| Profit before tax | 308 | 290 | 261 | 349 | 281 |
| Tax | 63 | 61 | 57 | −0 | 63 |
| Net profit | 245 | 230 | 205 | 283 | 218 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 361 | 11 746 | 13 147 | 12 648 | 8 469 |
| Equity | 7 070 | 7 300 | 7 504 | 6 873 | 7 092 |
| Long-term debt | 16 | 8 | — | 0 | 0 |
| Short-term debt | 1 275 | 4 439 | 5 642 | 5 775 | 1 378 |
| Total debt | 1 291 | 4 447 | 5 642 | 5 775 | 1 378 |
EBITDA margin
2.8%
This company
15.8%
Market median
-82% vs market
20202024
Equity ratio
83.7%
This company
38.2%
Market median
+119% vs market
20202024
Return on equity
3.1%
This company
18.4%
Market median
-83% vs market
20202024
Net profit margin
2.7%
This company
8.1%
Market median
-67% vs market
20202024
Asset turnover
0.96×
This company
1.12×
Market median
+14% vs market
20202024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LK Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (5) | ||
SL Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
JM Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
HR Chief Executive Officer | Chief Executive Officer | 2023 – 2024 |
| Audit | 2014 – 2023 | |
KK Chief Executive Officer | Chief Executive Officer | 2018 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Chairperson | 2020 | |
| Former (3) | ||
| Chairperson | 2018 – 2020 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2018 – 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mundipharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Salvador López Orland | Chief Executive Officer | 0 companies |
| Jennie Maria Synnöve Tjernström | Chief Executive Officer | 0 companies |
| Lisbeth Kattenhoj | Chief Executive Officer | 0 companies |
| Hywel Rhys Day | Chief Executive Officer | 0 companies |
| Bengt Christer Valdemar Nyholm | Audit | 0 companies |
| Kjetil Kollstad | Chief Executive Officer | 0 companies |
| Stuart David Baker | Chairperson | 0 companies |
| Floris Anne Everard Bongenaar | Board of Directors | 0 companies |
| Outi Elisabeth Raitasuo | Board of Directors | 0 companies |
| Åke Gunnar Wikström | Board of Directors | 0 companies |
| Stephen Johan Jamieson | Chairperson | 0 companies |